Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5VTB9
UPID:
RN220_HUMAN
Alternative names:
RING finger protein 220; RING-type E3 ubiquitin transferase RNF220
Alternative UPACC:
Q5VTB9; B3KPJ3; B4DLZ9; E9PCS1; Q4KMX2; Q9NVP6
Background:
E3 ubiquitin-protein ligase RNF220, also known as RING finger protein 220, plays a pivotal role in cellular processes through its E3 ligase activity and stabilization of CTNNB1, enhancing Wnt signaling. It is instrumental in the regulation of nuclear lamina, highlighting its multifaceted role in cellular integrity and signaling pathways.
Therapeutic significance:
The protein's involvement in Leukodystrophy, hypomyelinating, 23, with ataxia, deafness, liver dysfunction, and dilated cardiomyopathy underscores its potential as a therapeutic target. Understanding the role of E3 ubiquitin-protein ligase RNF220 could open doors to potential therapeutic strategies for this neurodegenerative disorder.